Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects

NCT00434733 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4400

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Pandemic influenza vaccine

Sponsor

Novartis

Collaborators

[object Object]